Keppra (Levetiracetam)

Levetiracetam works by binding to the synaptic vesicle protein 2A (SV2A) on presynaptic neurons. This binding modulates the release of neurotransmitters, stabilising synaptic activity and decreasing neuronal hyper‑excitability that can trigger seizures. The exact downstream pathways are still being studied, but SV2A interaction is central to its antiepileptic effect.

The dosage of Keppra is individualized and must be determined by a qualified prescriber. Factors such as the patient’s age, weight, renal function, and specific seizure type influence the prescribed amount. Healthcare professionals will calculate the appropriate dose and any necessary adjustments.

Safety data for levetiracetam in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider before starting or continuing therapy.

To order Keppra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Keppra differs from many traditional antiepileptics such as carbamazepine or valproate because it has a unique mechanism involving SV2A binding and does not significantly affect hepatic enzyme systems. This often results in fewer drug‑drug interactions and a more favourable side‑effect profile, although individual response varies and treatment choice should be guided by the clinician.

Keppra tablets should be stored at ambient temperature, preferably below 25 °C, in the original packaging to protect them from moisture and light. Keep the container tightly closed and out of reach of children. No refrigeration is required for this oral tablet formulation.

Keppra is taken orally as a tablet. The tablet should be swallowed whole with a glass of water and can be taken with or without food, unless otherwise directed by the prescriber. The exact timing and frequency are determined by the treating physician based on the patient’s therapeutic needs.

The most serious risks include severe allergic reactions such as Stevens‑Johnson syndrome, life‑threatening skin rashes, and psychiatric effects like new or worsening depression, anxiety, or suicidal thoughts. Patients should be monitored closely for any signs of these reactions and seek immediate medical attention if they occur.

Keppra should be avoided in individuals with a known hypersensitivity to levetiracetam or any of its excipients. Patients with severe renal impairment may require special dosing considerations and should be evaluated by a healthcare professional before use. As always, the prescriber will assess suitability on a case‑by‑case basis.